BACKGROUND: Randomized control trials and observational studies show high-quality warfarin therapy leads to safe and effective stroke prophylaxis. In usual community practice, patient, physician and health care system factors are barriers to optimal anticoagulation. We examined the predictive relationship between inpatient and outpatient INR values in chronic non-valvular atrial fibrillation (AF) patients hospitalized for ischemic stroke (S), bleed (B) and control events (C) in usual community practice. METHODS: This nested case-control analysis identified AF patients hospitalized for S, B and C using medical and pharmacy claims spanning 4.5 years ('98-'03) and validating diagnosis with chart abstraction. AF was defined as 2 medical claims for AF >or= 42 days apart with a related prescription claim for warfarin. INRs from both outpatient and inpatient settings were used to yield a continuous history of coagulation status. Time-in-therapeutic-range (TTR) was calculated by Rosendaal's linear interpolation method. Correlation of inpatient and prognostic utility of last outpatient INRs was tested with S or B hospitalizations using univariate and multivariate logistic regression. RESULTS: Overall, 614 hospitalizations (means: age 73.9, CHADS(2) = 3.24; 52% male) included S (n = 98), B (n = 101) and C (n = 415) events. Average TTR was 28.6% (49.4% at INR <2.0, 21.9% at INR >3.0). First INR on admission (INR <2.0 or >3.0) was associated with S and B hospitalizations (OR-adjusted [95%CI], 1.68 [1.04-2.73] and 1.72 [1.02-2.90]), respectively. Last outpatient INR <2.0 was not associated with S (OR-adjusted [95%CI], 1.12 [0.77-1.81]), and INR >3.0 was not associated with B (OR-adjusted [95%CI], 1.25 [0.67-2.32]). Last outpatient INR measurement occurred at 28, 22 and 24 days (median; S, B & C, respectively) before hospitalization. CONCLUSION: Patients were observed within therapeutic range less than 30% of their time on warfarin. While inpatient INRs were clearly associated with both ischemic stroke and bleed events, last outpatient INR before event was not predictive.
BACKGROUND: Randomized control trials and observational studies show high-quality warfarin therapy leads to safe and effective stroke prophylaxis. In usual community practice, patient, physician and health care system factors are barriers to optimal anticoagulation. We examined the predictive relationship between inpatient and outpatient INR values in chronic non-valvular atrial fibrillation (AF) patients hospitalized for ischemic stroke (S), bleed (B) and control events (C) in usual community practice. METHODS: This nested case-control analysis identified AFpatients hospitalized for S, B and C using medical and pharmacy claims spanning 4.5 years ('98-'03) and validating diagnosis with chart abstraction. AF was defined as 2 medical claims for AF >or= 42 days apart with a related prescription claim for warfarin. INRs from both outpatient and inpatient settings were used to yield a continuous history of coagulation status. Time-in-therapeutic-range (TTR) was calculated by Rosendaal's linear interpolation method. Correlation of inpatient and prognostic utility of last outpatient INRs was tested with S or B hospitalizations using univariate and multivariate logistic regression. RESULTS: Overall, 614 hospitalizations (means: age 73.9, CHADS(2) = 3.24; 52% male) included S (n = 98), B (n = 101) and C (n = 415) events. Average TTR was 28.6% (49.4% at INR <2.0, 21.9% at INR >3.0). First INR on admission (INR <2.0 or >3.0) was associated with S and B hospitalizations (OR-adjusted [95%CI], 1.68 [1.04-2.73] and 1.72 [1.02-2.90]), respectively. Last outpatient INR <2.0 was not associated with S (OR-adjusted [95%CI], 1.12 [0.77-1.81]), and INR >3.0 was not associated with B (OR-adjusted [95%CI], 1.25 [0.67-2.32]). Last outpatient INR measurement occurred at 28, 22 and 24 days (median; S, B & C, respectively) before hospitalization. CONCLUSION:Patients were observed within therapeutic range less than 30% of their time on warfarin. While inpatient INRs were clearly associated with both ischemic stroke and bleed events, last outpatient INR before event was not predictive.
Authors: Vincent J Willey; Michael F Bullano; Ole Hauch; Matthew Reynolds; Gail Wygant; Lauren Hoffman; George Mayzell; Alex C Spyropoulos Journal: Clin Ther Date: 2004-07 Impact factor: 3.393
Authors: Daniel E Singer; Gregory W Albers; James E Dalen; Alan S Go; Jonathan L Halperin; Warren J Manning Journal: Chest Date: 2004-09 Impact factor: 9.410
Authors: Fátima Rodriguez; Clemens Hong; Yuchiao Chang; Lynn B Oertel; Daniel E Singer; Alexander R Green; Lenny López Journal: J Am Heart Assoc Date: 2013-07-05 Impact factor: 5.501
Authors: M Elle Saine; Dena M Carbonari; Craig W Newcomb; Melissa S Nezamzadeh; Kevin Haynes; Jason A Roy; Serena Cardillo; Sean Hennessy; Crystal N Holick; Daina B Esposito; Arlene M Gallagher; Harshvinder Bhullar; Brian L Strom; Vincent Lo Re Journal: BMC Pharmacol Toxicol Date: 2015-04-02 Impact factor: 2.483
Authors: Vincent Lo Re; Dena M Carbonari; M Elle Saine; Craig W Newcomb; Jason A Roy; Qing Liu; Qufei Wu; Serena Cardillo; Kevin Haynes; Stephen E Kimmel; Peter P Reese; David J Margolis; Andrea J Apter; K Rajender Reddy; Sean Hennessy; Harshvinder Bhullar; Arlene M Gallagher; Daina B Esposito; Brian L Strom Journal: BMJ Open Diabetes Res Care Date: 2017-07-31
Authors: Julius Chacha Mwita; Albertino Damasceno; Pilly Chillo; Okechukwu S Ogah; Karen Cohen; Anthony Oyekunle; Endale Tefera; Joel Msafiri Francis Journal: BMJ Open Date: 2022-02-01 Impact factor: 2.692